UTI Healthcare Fund Direct Growth

Equity
Direct
Sector - Healthcare
UTI Healthcare Fund Direct Growth

About the Fund

UTI Healthcare Fund Direct Growth is an equity fund. This fund was started on 1 January, 2013. The fund is managed by . The fund could potentially beat inflation in the long-run.

Key Parameters

  1. UTI Healthcare Fund Direct Growth has ₹986 Cr worth of assets under management (AUM) as on Jun 2024 and is less than category average.
  2. The fund has an expense ratio 1.3.

Returns

UTI Healthcare Fund Direct Growth has given a CAGR return of 16.57% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 48.37%, 15.13% and 27.72% respectively.

Holdings

UTI Healthcare Fund Direct Growth has allocated its funds majorly in Health, Cash Equivalent, Government, Financial Services, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd, Ajanta Pharma Ltd, Apollo Hospitals Enterprise Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of UTI Healthcare Fund Direct Growth

The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. UTI Healthcare Fund Direct Growth has no lock in period.

Fund Performance
zero opening, trading, fund transfer fee
189 people have invested ₹ 15.3L in UTI Healthcare Fund Direct Growth in the last three months

INDmoney Rank

Powered by IND quant engine
IND ranking is not available for this fund.
img
Beats FD returns for both 3Y & 5Y duration
img
5Y returns in the bottom 25% of the category
img
3Y returns in the bottom 25% of the category

Fund Overview

Expense ratio1.3%
Benchmark
S&P BSE Healthcare PR
AUM₹986 Cr
Inception Date1 January, 2013
Min Lumpsum/SIP₹5000/₹500
Exit Load
1%
Lock InNo Lock-in
TurnOver
24.9%
Risk
Risk meter
pointer
Very High Risk

Fund Distribution
as on (30-Jun-24)

  • Equity 98.5%

  • Debt & Cash 1.5%

Small cap
35.4%
Large cap
33.4%
Mid cap
28.6%
Sector Allocation

Jun'24

May'24

Apr'24

Health
97%
Financial Services
1.7%
Basic Materials
1.4%
All changes are between Apr'24 and Jun'24

as on (30-Jun-24)

  • Equity

Holdings
Weight%
1M Change
Sun Pharmaceuticals Industries Ltd
Sun Pharmaceuticals Industries Ltd
11.34%
-3.3%
Cipla Ltd
Cipla Ltd
6.61%
0%
Dr Reddy's Laboratories Ltd
Dr Reddy's Laboratories Ltd
5.66%
11.4%
Ajanta Pharma Ltd
Ajanta Pharma Ltd
5.29%
-4.7%
Apollo Hospitals Enterprise Ltd
Apollo Hospitals Enterprise Ltd
4.07%
-4.7%
See all

  • Returns %

  • Fund Ratios

  • Overview

Funds
1Y Returns
3Y Returns
5Y Returns
Since Inception
UTI Healthcare Fund Direct Growth
UTI Healthcare Fund Direct Growth
48.4%
15.1%
27.7%
16.6%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
52.3%
18.8%
30.4%
24.1%
DSP Healthcare Fund Direct Growth
DSP Healthcare Fund Direct Growth
46.2%
18.7%
31.5%
27.4%
LIC MF Healthcare Fund Direct Growth
LIC MF Healthcare Fund Direct Growth
45.1%
11.6%
23.8%
21.3%
See all

Returns for the month of Jun

  • Gainers

  • Losers

Top Growth Drivers
1M Return
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd
24%
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd
13.4%
Sun Pharmaceuticals Industries Ltd
Sun Pharmaceuticals Industries Ltd
7.2%

Mutual Fund Insights

Insights icon
Over the last 1 year, this fund has decreased expense ratio by 13.3% moving from 1.50 to 1.30.
Insights icon
In the last 1 year, Quant Healthcare Fund Direct Growth has given 60.96% return, outperforming this fund by 12.58%.
Insights icon
Over the last 1 month, this fund has experienced a 5.0% growth in AUM moving from 938.43 Cr to 985.8 Cr.
Insights icon
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.3% which is lower than the category average expense ratio of 1.42%.
Insights icon
In the last 3 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 18.75% return, outperforming this fund by 3.62% per annum.
Insights icon
In the last 5 years, DSP Healthcare Fund Direct Growth has given 31.51% return, outperforming this fund by 3.78% per annum.

UTI Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 16.57% since inception which is less than its category average return of 23.79%
Fund Allocations

Fund Allocations

This fund has an allocation of 98.5% in Equity, 0.13% in Debt and 1.38% in Cash related instruments
AUM size ₹986 Cr

AUM size ₹986 Cr

This fund has AUM of ₹986 Cr which is less than its category average of ₹ 1743 Cr
Expense Ratio 1.3%

Expense Ratio 1.3%

This fund has an expense ratio of 1.3% which is less than its category average expense ratio of 1.44%

Frequently Asked Questions

The current NAV of UTI Healthcare Fund Direct Growth is ₹282.92 as on 25-Jul-2024.
Existing (Absolute + CAGR) as on 25-Jul-2024.
UTI Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
7.47%
7.47%
6 Month Returns
17.89%
17.89%
1 Year Returns
48.37%
48.37%
3 Years Returns
52.62%
15.13%
5 Years Returns
239.9%
27.72%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
1.3% as on June 2024
₹986 Cr as on June 2024
Sun Pharmaceuticals Industries Ltd(11.34%), Cipla Ltd(6.61%), Dr Reddy's Laboratories Ltd(5.66%), Ajanta Pharma Ltd(5.29%), Apollo Hospitals Enterprise Ltd(4.07%) as on June 2024
Health(95.52%), Financial Services(1.63%), Basic Materials(1.35%) as on June 2024
The alpha ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
UTI Healthcare Fund Direct Growth
2.27
0.44
2.2
As on June 2024
The alpha for UTI Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
UTI Healthcare Fund Direct Growth
0.91
0.92
0.92
As on June 2024
The Beta for UTI Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
UTI Healthcare Fund Direct Growth
2.2
0.59
1.07
As on June 2024
The sharpe ratio for UTI Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
UTI Healthcare Fund Direct Growth
14.1
14.44
18.2
As on June 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 0.99 as on June 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
The Exit load of UTI Healthcare Fund Direct Growth is 1%